We are live on ! Find out more
LAB icon

Standard BioTools
LAB

144 hedge funds and large institutions have $480M invested in Standard BioTools in 2024 Q2 according to their latest regulatory filings, with 35 funds opening new positions, 39 increasing their positions, 35 reducing their positions, and 34 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,045% more call options, than puts

Call options by funds: $1.26M | Put options by funds: $110K

11% more repeat investments, than reductions

Existing positions increased: 39 | Existing positions reduced: 35

3% more first-time investments, than exits

New positions opened: 35 | Existing positions closed: 34

1% less funds holding

Funds holding: 145 → 144 (-1)

18.23% less ownership

Funds ownership: 91.46% → 73.23% (-18%)

33% less capital invested

Capital invested by funds: $719M → $480M (-$239M)

50% less funds holding in top 10

Funds holding in top 10: 4 → 2 (-2)

Holders
144
Holders Change
-1
Holders Change %
-0.69%
% of All Funds
2.08%
Holding in Top 10
2
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-50%
% of All Funds
0.03%
New
35
Increased
39
Reduced
35
Closed
34
Calls
$1.26M
Puts
$110K
Net Calls
+$1.15M
Net Calls Change
-$1.96M

Top Buyers

1
BlackRock
BlackRock
New York
+$39.8M
2
Morgan Stanley
Morgan Stanley
New York
+$13M
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$9.99M
4
State Street
State Street
Massachusetts
+$7.32M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$7.26M

Top Sellers

1
ICM
Indaba Capital Management
California
-$20M
2
Millennium Management
Millennium Management
New York
-$19.9M
3
Balyasny Asset Management
Balyasny Asset Management
Illinois
-$9.4M
4
Goldman Sachs
Goldman Sachs
New York
-$6.44M
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$4.58M
Name Holding Trade Value Shares
Change 		Change in
Stake
Citadel Advisors
26
Citadel Advisors
Florida
$1.6M +$2.21M +905,346 New
GS
27
Gagnon Securities
New York
$1.59M +$106K +43,364 +5%
Charles Schwab
28
Charles Schwab
California
$1.5M +$1.8M +735,771 +659%
N
29
Nuveen
North Carolina
$1.39M +$1.91M +783,152 New
PCP
30
Pacific Capital Partners
$1.33M +$1.83M +750,000 New
MF
31
Magnetar Financial
Illinois
$1.23M -$2.01M -822,392 -54%
GA
32
Gagnon Advisors
New York
$1.19M – – –
Goldman Sachs
33
Goldman Sachs
New York
$1.13M -$6.44M -2,636,730 -80%
Walleye Capital
34
Walleye Capital
New York
$994K +$1.37M +561,521 New
PCMI
35
Paradigm Capital Management Inc
New York
$974K – – –
Swiss National Bank
36
Swiss National Bank
Switzerland
$865K +$147K +60,200 +14%
IP
37
Intellectus Partners
California
$743K -$9.33K -3,816 -0.9%
Assenagon Asset Management
38
Assenagon Asset Management
Luxembourg
$740K -$392K -160,522 -28%
RG
39
Redmile Group
California
$729K – – –
RhumbLine Advisers
40
RhumbLine Advisers
Massachusetts
$721K +$970K +396,719 +3,691%
Two Sigma Investments
41
Two Sigma Investments
New York
$714K -$595K -243,411 -38%
UBS AM
42
UBS AM
Illinois
$677K +$681K +278,428 +268%
Dimensional Fund Advisors
43
Dimensional Fund Advisors
Texas
$641K -$2.21M -904,474 -71%
AllianceBernstein
44
AllianceBernstein
Tennessee
$559K +$772K +315,690 New
JJ
45
Johnson & Johnson
New Jersey
$552K – – –
Squarepoint
46
Squarepoint
New York
$541K +$422K +172,738 +130%
RA
47
Royce & Associates
New York
$538K +$744K +304,231 New
AGM
48
Alpine Global Management
New York
$520K +$718K +293,706 New
CAC
49
Cowen and Company
New York
$486K – – –
Bank of America
50
Bank of America
North Carolina
$456K -$926K -378,659 -60%
1
2
3 4 5

LAB Hedge Fund Activity: Q2 2024 in Review

144 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Standard BioTools (LAB) for Q2 2024, worth a combined $480M — down 33% from $719M a quarter earlier.

Buyers outnumbered sellers: 35 funds opened new LAB positions and 34 closed out — a net gain of 1 holder — while 39 added to existing stakes and 35 trimmed.

The largest buyer was BlackRock, adding an estimated $39.8M. The largest seller was Indaba Capital Management, exiting entirely with an estimated $20M sold.

  • 144 institutional investors held Standard BioTools (LAB) as of Q2 2024, down from 145 in Q1 2024.
  • Funds reported $480M of Standard BioTools stock for Q2 2024, down 33% quarter-over-quarter.
  • 35 funds opened new Standard BioTools positions in Q2 2024 and 34 closed out, a net change of +1 holder.
  • The largest Standard BioTools buyer in Q2 2024 was BlackRock, an estimated $39.8M added.
  • The largest Standard BioTools seller in Q2 2024 was Indaba Capital Management, an estimated $20M sold.

Based on aggregated 13F filings for Q2 2024.